New Delhi, November 24, 2022: Eli Lilly and Company (India) Pvt. Ltd. (?Lilly India?) has announced the launch of the additional indication for Ramiven? (abemaciclib), following approval from The Drug Controller General of India (DCGI) in combination with endocrine therapy for adjuvant treatment in adult patients with hormone receptor (HR)positive, human epidermal growth factor receptor 2(HER2) negative, node-positive early breast cancer (EBC) at high risk of recurrence.
CDK 4/6 inhibitors are a class of medicines used to treat certain types of metastatic breast cancers. In India, over 50,000 patients are diagnosed with HR+/HER2- early breast cancer (EBC) every year. Close to 30% of EBC patients with high-risk clinical or pathological features experience recurrence or metastasis despite receiving standard therapy.
Vineet Gupta, Managing Director, Eli Lilly and Company - India & India Subcontinent, said, ?Breast cancer is the cancer which is most prevalent amongst women in India. It significantly impacts the quality of life of survivors and their families, who live with the fear of recurrence. The approval of Ramiven? for treatment of Early Breast Cancer brings more optimism by providing a new treatment option to the healthcare professionals for their patients.?
Ramiven? is already approved for the treatment of certain types of HR+ HER2- advanced or metastatic breast cancer.
Ramiven? is a prescription drug to be used only on the advice of an oncologist and under medical supervision. It is available in tablet strengths of 200 mg, 150 mg, 100 mg, and 50 mg.
About early breast cancer (EBC)
Early breast cancer (EBC) is cancer that has not spread beyond the breast or underarm lymph nodes. The most common type of breast cancer is HR+, HER2-. Most EBC is treatable and does not return. However, there are many factors that may influence whether the breast cancer returns. Risk of recurrence is greatest within the initial two to three years post-diagnosis, particularly in patients with node-positive, high risk EBC. Factors associated with high risk of recurrence include positive nodal status, large tumor size (≥5 cm), high tumor grade (Grade 3), and high rate of cellular proliferation [Ki-67 score (≥20%). Node-positive means that cancer cells from the tumor in the breast have been found in the lymph nodes in the armpit area. Although the breast cancer is removed through surgery, the presence of cancer cells in the lymph nodes indicate that there is a higher chance of the cancer returning and spreading.
Ramiven? (abemaciclib) is a targeted treatment known as a CDK4/6 inhibitor. Ramiven? is a non-chemotherapy oral tablet.
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
About Eli Lilly India
Eli Lilly and Company (India) Pvt. Ltd. (Lilly India), headquartered in Gurgaon, is a wholly owned subsidiary of Eli Lilly and Company, a global biopharmaceutical company headquartered in Indianapolis, USA. Since its inception more than 25 years ago, Lilly India has been committed to offer advanced treatment options to treat chronic diseases such as diabetes, lung cancer, gastric cancer, osteoporosis, rheumatoid arthritis, men?s health, and growth-hormone deficiency.
User :- Abhishek Verma